Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy

Journal of Neuro-Oncology

Volumn 102, Issue 3, 2011, Pages 443-449

  Iwadate, Yasuo ^a   Matsutani, Tomoo ^a   Hasegawa, Yuzo ^a   Shinozaki, Natsuki ^a   Higuchi, Yoshinori ^a   Saeki, Naokatsu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

1p 19q; Chemotherapy; Leukoencephalopathy; Neurotoxicity; Oligodendroglial tumor; PCV

Indexed keywords

NIMUSTINE; NITROSOUREA; PROCARBAZINE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; BRAIN ATROPHY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HISTOLOGY; HUMAN; LEUKOPENIA; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LONGITUDINAL STUDIES; LOSS OF HETEROZYGOSITY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; RADIOTHERAPY; YOUNG ADULT;

EID: 79958212496     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0340-4     Document Type: Article

References (39)

1. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F, Stenning S, Pierart M, Van Glabbeke M (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade gliomas in the adult: European Organization for Research and Treatment of Cancer Study 22845 with Medical Research Council Study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52:316-324 (Pubitemid 34170840)
2. Shaw E, Arusell R, Scheithauer B et al (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Group study. J Clin Oncol 20:2267-2276 (Pubitemid 34441653)
3. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985-990 (Pubitemid 41323034)
4. Papagikos MA, Shaw EG, Stieber VW (2005) Lessons from randomized clinical trials in adult low grade glioma. Lancet Oncol 6:240-244 (Pubitemid 40450715)
5. Behin A, Hoang-Xuan K, Carpentier AF, Delattre J-Y (2003) Primary brain tumors in adults. Lancet 361:323-331
6. Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A (2003) Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2:395-403 (Pubitemid 36793931)
7. Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J, Pestana A, Rey JA (1994) Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 57:172-175 (Pubitemid 24144204)
8. Caincross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714 (Pubitemid 46630566)
9. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722 (Pubitemid 46630567)
10. Hoang-Xuan K, Capelle L, Kujas M et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138 (Pubitemid 41103727)
11. Kanner AA, Staugaitis SM, Castilla EA et al (2006) The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 104:542-550
12. Mariani L, Deiana G, Vassella E, Fathi AR, Murtin C, Arnold M, Vajtai I, Weis J, Siegenthaler P, Schobesberger M, Reinert MM (2006) Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 24:4758-4763 (Pubitemid 46630940)
13. Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC (2006) Current strategies in treatment of oligodendroglioma: evolution of molecular signature of response. J Clin Oncol 24:1246-1252 (Pubitemid 46622027)
14. Weller M, Berger H, Hartmann C et al (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933-6937
15. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360-369 (Pubitemid 351782844)
16. Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas. Predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831-1836
17. Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G (2009) Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol 53:305-309
18. Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendrogliomas respond to chemotherapy. Neurology 46:203-207
19. Higuchi Y, Iwadate Y, Yamaura A (2004) Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology 63:2384-2386 (Pubitemid 40024356)
20. Sunyach MP, Jouvet A, Perol D, Jouanneau E, Guyotat J, Gignoux L, Carrie C, Frappaz D (2007) Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol 85:319-328 (Pubitemid 350147683)
21. Bromberg JEC, van den Bent MJ (2009) Oligodendrogliomas: molecular biology and treatment. Oncologist 14:155-163
22. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
23. Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861 (Pubitemid 44672036)
24. Shaw EG, Scheithauser BW, O'Fallon JR, Tazellar HD, Davis DH (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428-434
25. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35:1018-1034
26. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, Cairncross G (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294-1301 (Pubitemid 27167360)
27. Leonardi MA, Lumenta CB (2001) Oligodendrogliomas in CT/MR-era. Acta Neurochir 143:1195-1203
28. Okamoto Y, Di Patre OL, Birkhard C et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49-56 (Pubitemid 38961073)
29. Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, Michiels JF, Bourg V, Paquis P, Chatel M, Frenay M, Nice Brain Tumor Study Group (2004) Long-term outcome of oligodendrogliomas. Neurology 62:1783-1787 (Pubitemid 38661735)
30. Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, Huang EY (2002) Treatment outcome and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 54:1405-1409
31. Kang H-C, Kim IH, Eom K-Y, Kim JH, Jung H-W (2009) The role of radiotherapy in the treatment of newly diagnosed supratentorial low-grade oligodendrogliomas: comparative analysis with immediate radiotherapy versus surgery alone. Cancer Res Treat 41:132-137
32. Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442-1448 (Pubitemid 30210463)
33. Ozyigit G, Onal C, Gurkaynak M, Soylemezoklu F, Zorlu F (2005) Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients. J Neurooncol 75:189-193 (Pubitemid 41819724)
34. El-Hatter H, Souhami L, Roberge D, Del Maestro R, Leblanc R, Eldebawy E, Muanza T, Melancon D, Kavan P, Guiot MC (2009) Low-grade oligodendroglioma: an indolent but incurable disease? J Neurosurg 111:265-271
35. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ (2005) Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103:802-809 (Pubitemid 40216410)
36. Ty AU, See SJ, Rao JP, Khoo JB, Wong MC (2006) Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience. Neurology 66:247-249
37. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M (2007) Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14:391-398 (Pubitemid 46481159)
38. Buckner JC, Geame D, O'Fallon JR et al (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low grade oligodendroglioma and oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251-255 (Pubitemid 46606153)
39. Postma TJ, van Groeningen CJ, Witjes RJ, Weerts JG, Kralendonk JH, Heimans JJ (1998) Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 38:69-75 (Pubitemid 28107894)